New Medicare cap on anemia drugs could hammer Amgen

In another body blow to Amgen, regulators at Medicare say they have proposed limiting the amount of anemia drugs that it will reimburse for. Amgen reports that sales have already been sliding for anemia drugs and the regulators say that federal reimbursements are likely to drop 10 percent on the new rules. Medicare spends more money on anemia drugs than for any other pharmaceutical. Aranesp and Epogen, marketed by Amgen and J&J, bring in more than $10 billion a year and account for about half of Amgen's sales. That money has built Amgen into the biggest biotech company in the world and funded many of its new development programs.

- here's the report on the new rules from the Los Angeles Times
-
and here's the report from The Wall Street Journal

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.